Dimerix Share Price and Company Fundamentals



Price
$0.26
Change
0.010 (4.000%)
52 week
0.13 - 0.78

Last traded: Today at 1:53 AM

Dimerix Limited, a biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. It offers DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis; and DMX-700, which is in pre-clinical stage for the treatment of chronic obstructive pulmonary disease, as well as proprietary ReceptorHIT assay technology. The company was incorporated in 1975 and is headquartered in Fitzroy, Australia.

Key Metrics

PE ratio

-

PB ratio

14.44

Dividend yield

Beta

1.29

Market cap

$51.48M

Enterprise value

$45.6M

Company profile

Primary activitiesA Clinical stage (Phase II) biotechnology business commercialising new therapies for under-served and unmet medical needs globally
Industry / SectorBiotechnology / Healthcare
Websitehttp://dimerix.com
Mailing address425 Smith Street Fitzroy VIC 3065 Australia
Phone / Fax61 3 0081 3321 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Dimerix does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Dimerix.

NameTitleAgeTotal Pay
Dr. James Howard Williams M.B.A., BSc (Hons), Ph.D., MBA, GAICDExec. Chairman5080k
Dr. Nina Webster Ph.D., M.IP.Law, MBACEO, MD & Director425.07k
Mr. Hamish George B.Com., C.A.CFO & Company Sec.
Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D.Chief Scientific Advisor
Ms. Elizabeth McCall B.Com., L.L.B., LLB., B.Juris, B.Com(Hons), GAICDBus. Devel. Officer

Profitability and management effectiveness

Profit margin

-223.44%

Operating margin

-226.81%

Return on assets

-77.34%

Return on equity

-158.38%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Dimerix is 51.48M and its enterprise value is 45.6M. The enterprise value to revenue ratio of DXB is 18.46.

The DXB's stocks Beta value is 1.29 making it 29% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Dimerix (DXB)

Dimerix (ASX:DXB) Frequently Asked Questions

1. What is Dimerix's Stock Symbol?

Dimerix trades on ASX under the ticker symbol "DXB".

2. What is Dimerix's stock price today?

One share of DXB stock can currently be purchased for approximately $0.26.

3. How can I contact Dimerix?

Dimerix's mailing address is 425 Smith Street Fitzroy VIC 3065 Australia. The company can be reached via phone at 61 3 0081 3321.

4. What is Dimerix's official website?

The official website of Dimerix is http://dimerix.com.

5. Which share registry manages Dimerix's stock?

Dimerix's stock is managed by AUTOMIC REGISTRY SERVICES.